Literature DB >> 15732104

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

Maria Isabel Leite1, Philipp Ströbel, Margaret Jones, Kingsley Micklem, Regina Moritz, Ralf Gold, Erik H Niks, Sonia Berrih-Aknin, Francesco Scaravilli, Aurea Canelhas, Alexander Marx, John Newsom-Davis, Nick Willcox, Angela Vincent.   

Abstract

In generalized myasthenia gravis (MG) patients without detectable acetylcholine receptor (AChR) antibodies (SNMG), the thymus is often reported as "normally involuted." We analyzed thymic compartments in 67 patients with generalized MG, with AChR antibodies (AChR+, n = 23), with muscle-specific kinase (MuSK) antibodies (MuSK+, n = 14) or with neither (MuSK-, n = 30), and in 11 non-MG controls. Four of 14 MuSK+ thymi had rare small germinal centers, but overall they were not different from age-matched controls. However, approximately 75% MuSK- samples showed lymph node-type infiltrates similar to those in AChR+ patients, but with fewer germinal centers. These variations may explain some apparent differences in responses to thymectomy in SNMG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15732104     DOI: 10.1002/ana.20386

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  59 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

3.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

4.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

5.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

6.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

7.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.

Authors:  Alexandra Pevzner; Benedikt Schoser; Katja Peters; Nicoleta-Carmen Cosma; Andromachi Karakatsani; Berthold Schalke; Arthur Melms; Stephan Kröger
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

Review 8.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

9.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

10.  Autoantibodies in neuromuscular transmission disorders.

Authors:  Angela Vincent
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.